Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun pharma, Dr Reddys,...

    Sun pharma, Dr Reddys, others deny allegations of price fixing in US

    GarimaWritten by Garima Published On 2019-05-16T09:35:06+05:30  |  Updated On 16 Aug 2021 12:12 PM IST

    In separate clarifications to stock exchanges, the companies including Glenmark, Sun Pharma, Dr Reddy's, Aurobindo Pharma denied the accusations and stated they would defend themselves in the matter.


    New Delhi: The homegrown drugmakers including Dr Reddy's, Wockhardt, Aurobindo, Glenmark and Sun Pharma named in an anti-trust lawsuit in the US has recently denied allegations of engaging in a conspiracy to fix prices.


    Medical Dialogues had earlier reported that in a major setback, a group of domestic pharmaceutical companies including Zydus Cadila, Lupin, Aurobindo Pharma, Dr Reddy's Labs, Wockhardt, Glenmark, Sun Pharma were in a soup as 40 US states had filed legal proceedings against these pharma majors.


    Also Read: Inflated prices to 1000 per cent; Lupin, Sun Pharma, Dr Reddys, others face lawsuit


    The domestic drugmakers are among the 21 generic pharmaceutical firms and 15 other individual defendants against whom the Attorneys General of 49 US states, the Commonwealth of Puerto Rico and the District of Columbia had filed a complaint with respect to 116 generic drugs in the US District Court for the District of Connecticut.


    The companies have been accused of violating antitrust laws by fixing prices and allocating customers.

    In separate clarifications to stock exchanges, the companies denied the accusations and stated they would defend themselves in the matter.

    Dr Reddy's said, "We intend to vigorously defend against these allegations and are in the process of filing our response with the District Court of Connecticut."

    According to a report by PTI, the company said its US subsidiary is specifically named as a defendant with respect to five generic drugs (Ciprofloxacin HCL tablets, Glimepiride tablets, Oxaprozin tablets, Paricalcitol and Tizanidine), for an alleged "overarching conspiracy".


    It further said, "Currently, we do not foresee any material impact to our operations and consolidated results with respect to this matter."

    Sun Pharma in a regulatory filing said that its subsidiary Taro Pharmaceuticals USA Inc has been named in the second lawsuit filed by the states. "The allegations made in these lawsuits are without merit and our concerned subsidiaries will continue to vigorously defend against them," the company said in its clarification to stock exchanges over a news article.

    Sun Pharmaceutical Industries Limited has not been named in these litigations, the drug major clarified.

    Wockhardt also said anti-trust action relates to the price hike of various generic drugs. The company has denied such accusation at appropriate Forum and is vigorously defending against the matter.

    Similarly, Glenmark said in December 2016 a similar lawsuit was filed and the latest one includes some of the parties from the first one as well as additional parties with allegations of fixing prices of additional products which were not referenced in the first lawsuit, suggest a report by PTI.

    "While the company is currently reviewing the second suit, we expect to file papers with the Federal Court in due course denying the accusations. Given the early nature of the matter, the company does not anticipate the material impact of the same," Glenmark added.


    Aurobindo Pharma also said it is currently reviewing the second anti-trust lawsuit.

    "We expect that we will be filing papers with the Federal Court in due course denying each of the relevant accusations. Aurobindo does not, at this time, anticipate that these matters will have a material impact on the Company's operations or business results," it added.
    antidepressantsasthma medicationAurobindo Pharmablood thinnerscancer drugscontraceptivesdiabetesDr Reddy'sgeneric drugsGlenmarkhigh cholesterolHIVIndia Pharma companiesinflating priceinflationLupinMylanoral antibioticsPfizerpharma co conspiracyPharma companiesPharma companies IndiaPharma companies newsprescription medicinesSandozSun PharmaTaroTevaWockhardtzydus
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok